secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2025-04-30T23:59:59+00:00
Accession:  0001641172-25-006798
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Fertility reports 116% revenue growth to $6.5M in FY2024; adjusted EBITDA improves to $(2.2)M
--------------------------------------------------------------------------------

- Q4 2024 revenue $1.69M (+22% YoY); full-year revenue $6.53M (+116% YoY).
- Net loss widened to $(9.1)M in FY2024 from $(8.0)M, driven by NAYA Therapeutics merger costs.
- Adjusted EBITDA improved to $(2.2)M in FY2024 from $(4.9)M in FY2023.
- Company announced intent to divest majority stake in NAYA TX to refocus on fertility clinic operations.
- Management cites declining U.S. fertility rate and rising ART demand as expansion catalysts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/0001641172-25-006798-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000164117225006798/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-006798

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer